Skip to main content

Table 2 Summary of variables at baseline, 12 weeks, 1 year and 2 years of treatment

From: The effectiveness of Reslizumab in severe asthma treatment: a real-world experience

VariablesBaseline
(N=26)
12 weeks
(N=24)
1 year
(N=22)
2 year2
(N=11)
Mean ACQ-6 score ± SD3.50 ± 1.11.8 ± 1.71.7 ± 1.41.3 ± 1.1
 Mean improvement in ACQ-61.71.72.0
 P value<0.00010.00010.0001
Mean glucocorticoid dosea ± SD9.29 ± 4.324.79 ± 4.074.77 ± 4.534.62 ± 3.59
 Median reduction in the final oral glucocorticoid-% of baseline value50%50%50%
 Mean reduction of prednisolone dose ± SD4.50 ± 3.855.23 ± 4.804.12 ± 4.06
 P Value0.00080.00480.0239
Mean percent of FEV1 predicted value (before bronchodilation) +- SD62.08% ± 19.8564.51% ± 25.3070.61% ± 15.4074.91 ± 22.63
 Mean improvement in FEV1 percent of predicted value6.2811.9512.14
 P value0.360.0180.0021
Average number of exacerbationsb ± SD8.32 ± 4.681.74 ± 2.130.91 ± 0.70
 Mean reduction in annual Exacerbationsb ± SD7.26 ± 4.746.64 ± 3.29
 P Value<0.0001<0.0001
Mean peripheral blood Eosinophils countc ± SD0.78 ± 0.510.05 ± 0.030.05 ± 0.040.04 ± 0.03
 Mean reduction of eosinophils counts0.73 ± 0.520.74 ± 0.570.72 ± 0.63
 P Value<0.0001<0.00010.0057
  1. ACQ-6 Asthma Control Questionnaire, FEV1 Forced Expiratory Volume in 1 second
  2. aPrednisolone dose in mg
  3. bAverage number of exacerbations per year that required rescue systemic steroids course or increase in the maintenance steroid dose
  4. ccells X 109/L